HMGB1 signaling pathway in diabetes-related dementia: Blood-brain barrier breakdown, brain insulin resistance, and Aβ accumulation

Biomed Pharmacother. 2022 Jun:150:112933. doi: 10.1016/j.biopha.2022.112933. Epub 2022 Apr 9.

Abstract

Diabetes contributes to the onset of various diseases, including cancer and cardiovascular and neurodegenerative diseases. Recent studies have highlighted the similarities and relationship between diabetes and dementia as an important issue for treating diabetes-related cognitive deficits. Diabetes-related dementia exhibits several features, including blood-brain barrier disruption, brain insulin resistance, and Aβ over-accumulation. High-mobility group box1 (HMGB1) is a protein known to regulate gene transcription and cellular mechanisms by binding to DNA or chromatin via receptor for advanced glycation end-products (RAGE) and toll-like receptor 4 (TLR4). Recent studies have demonstrated that the interplay between HMGB1, RAGE, and TLR4 can impact both neuropathology and diabetic alterations. Herein, we review the recent research regarding the roles of HMGB1-RAGE-TLR4 axis in diabetes-related dementia from several perspectives and emphasize the importance of the influence of HMGB1 in diabetes-related dementia.

Keywords: Blood-brain barrier (BBB) breakdown; Brain insulin resistance; Diabetes-related dementia; High-mobility group box1 (HMGB1); Receptor for advanced glycation end-products (RAGE); Toll-like receptor 4 (TLR4).

Publication types

  • Review

MeSH terms

  • Blood-Brain Barrier / metabolism
  • Brain / metabolism
  • Dementia*
  • Diabetes Mellitus*
  • HMGB1 Protein* / metabolism
  • Humans
  • Insulin Resistance*
  • Receptor for Advanced Glycation End Products / metabolism
  • Signal Transduction
  • Toll-Like Receptor 4 / metabolism

Substances

  • HMGB1 Protein
  • Receptor for Advanced Glycation End Products
  • Toll-Like Receptor 4